Сравнение

Glepaglutide vs. Plecanatid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

нет данных

467426-54-6

Молекулярная масса

нет данных

1682 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Plecanatid

Plecanatide is structurally analogous to the body's own uroguanylin and, like it, activates the GC-C receptor at the gut surface, raising cGMP and fluid secretion. Its pH-dependent activity shifts the effect toward the proximal small intestine.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Glepaglutide	Plecanatid
Германия	Не одобрено	Не одобрено
США	Не одобрено	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Glepaglutide and Plecanatid?: Glepaglutide is classified as "Исследования (прочее)", while Plecanatid is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Plecanatid?: The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Plecanatid in Germany and the United States?: Германия: Glepaglutide — Не одобрено, Plecanatid — Не одобрено. США: Glepaglutide — Не одобрено, Plecanatid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Plecanatid

Германия

Не одобрено

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Glepaglutide and Plecanatid?

Glepaglutide is classified as "Исследования (прочее)", while Plecanatid is classified as "Исследования (прочее)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Plecanatid: Plecanatide is a 16-amino-acid analog of the body's own uroguanylin and a guanylate cyclase-C (GC-C) agonist. It is approved for chronic idiopathic constipation (CIC) and IBS with constipation (IBS-C). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Plecanatid?

The highest available evidence level is "РКИ на людях" for Glepaglutide and "РКИ на людях" for Plecanatid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Plecanatid in Germany and the United States?

Германия: Glepaglutide — Не одобрено, Plecanatid — Не одобрено. США: Glepaglutide — Не одобрено, Plecanatid — Рецептурный. These are factual summaries with source and review date on the individual pages.